Acticor Biotech SAS announces its participation in the European Stroke Organization Conference (ESOC) 2024, to be held from 15 to 17 May 2024 in Basel, Switzerland. ESOC is the leading European forum for stroke research and the preferred platform for the publication of major clinical trial data. As a reminder, ACTISAVE (NCT05070260) is an international, adaptive, multicenter, randomized, double-blind, placebo-controlled, parallel-group Phase 2/3 study evaluating the safety and efficacy of a single dose of glenzocimab used in combination with the standard of care (thrombolysis +/- thrombectomy) for acute ischemic stroke.

Deployed in the United States, Europe, Israel, and United Kingdom, ACTISAVE has enrolled 438 patients, of whom about 40% have undergone mechanical thrombectomy.